Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's Lymphoma

NCT00055640 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma

Interventions

BIOLOGICAL: rituximab
DRUG: cyclophosphamide
DRUG: doxorubicin hydrochloride
DRUG: prednisone
DRUG: vincristine sulfate
GENETIC: microarray analysis

Sponsor

Case Comprehensive Cancer Center

Collaborators

[object Object]